Morning, everyone. I am Marcelo, CFO of Ourofino Saúde Animal . It's a great pleasure to have you all here. All of our stockholders. We have the results of quarter four 2025. We have, starting with the CEO. We are going to talk a little about our goals. I'll come back later talking about our financial closing. Now we call Kleber.
Hello, good morning, Marcelo. Good morning, everyone. It's a pleasure to be here. It's a pleasure to be here to present to you the results of the quarter four of 2025. We are very proud of what we have delivered so far. It's a journey that comes from different decisions we have made. We have managed the company for the different angles. We are doing this to have the sales much more faster. We are closing the 2025 with positive results.
We are growing very fast and strong. It's very above the market. Totally different than we have seen. This is the fourth quarter, very consolidated. We grew around 20% of year. All the areas are growing with quality. We have here the net income growth, which is more than revenue. We had an adjusted growth, which brought a trajectory of values. We have a very elevated value. We had growth around 30%. This is important because we had a positive result, which we had enhanced all the revenues and also the revenues. We had a very long chain. Now we are going to present some results of five, four years ago. We have been showing the good results in 2024. Of course, 2025, we had a very good net revenue because we had very good products.
We're still having and enjoying the good results we have. I'm sure we have the products which will still bring good results. Of course, we have a few more. This is very important because it shows how good we are and how good we have been bringing. Of course, we have to remind that we just got this role because we had a very good beginning of the team, because we have a very passionate group. We are living the brand Ourofino every day. We are very happy with the results. I'm going to highlight some launching. Some things happened in the third quarter, but the others in the fourth one. We have some richer important information and revenue.
We had as in a very strategic with the Korean company. We have also a post-patent closing, which is the Nexlaner, which is for cows and which is a very complex treatment, which is very important for tropical agriculture and also when we talk about cattle and the European cattle, which suffers a lot with tick. We have WellPet, which is for companion pets. Some other products which are very differentiated from the other products in the market. We have here the WellPet, which is a pill, which is palatable. It has a protection period better than the other ones in the market. It's bringing with very easy access, which can bring the access to the ones who doesn't get this kind of protection because it brings a very good product. We have a very differentiated product.
We have another, which is Sincromais, which is a supplement, which enhance the fertility in the cattle, which is one of the leaders of the market. It comes here with very good importance in the market. We have also the vaccines. We had one which was launched this year, which is the second in the world. So, we have the BR market of this, which is the Brazilian. We have a very good market share, which is our vaccine cattle. We are also consolidating our strategies. When we go back analyzing our strategies in the market, you're going to remind that in 2025, we had highlighted the cattle and poultries. We have launched other products to these areas, and we are growing too. We grew more than 40%, and now we have grown 30%.
The focus we have been doing, it has been very important. That's just a summary of the year. It was in the year that we closed almost every indicators of the company. We are going to discuss this later on. Of course, it was a very good governance work, which has been very important. We are doing it ongoing. We also closed a very business cycle. Now we have 2030. We are accelerating the path to partnerships, international partnerships. This is very important. We have been working these strategies. We have very good work to be doing the product governance, seeing that we are in a very good path.
Later on, I'll be back in the Q&A. I'm going to pass the stage to Marcelo. Marcelo is with you now.
We have been seeing figures very well consolidated. We can see here in the fourth quarter 2024 and 2025, we have been growing. We had from in the accumulated, 19.5%. Something very important to understand, it's the second year in a row that we have been closing above our gross revenue, which we had in 27.7%. In comparison to the previous year, we had a growth. We had a very important net income, which was 17.2%, but we got 13.1%.
This reflects which was in a much more favorable year. We had many products which are now in the first or in the second position in market. We have been seeing this. We have seen the company going down the expenses, and this is important too. We had the EBITDA, which had 24.1%, but in the year was 27.7%. This reflects the reduced expenses of the company but also preserving the core in the search and development of the company. We have net income, which grew 17.2%. In the accumulated, we have 14.1%, which was in collection of capital, which is reflecting our profile of investment. We had the net income more than the company. We had the growth of the EBITDA and the income net growth more than the EBITDA as well.
We have a very detailed information here. The consolidated results we had in the quarter, a growth of 23.2% and accumulated as 19.5%. We have here a consolidated that was 40.6%, which is higher than the other years. It was the best net income in the animal segments. Always reminding the capacity of the company to generate value to the whole market. We have here the companion animals results. We have been following that in 2025, it was a little less warm, but we still have a very good growth, which was 10.4%, and we had a growth in the quarter in 24% that Kleber has mentioned previously. We had a growth in gross profit 71.3%. Reminding that the company has a very good ability and is room to grow this.
We had the net revenue that it grows to 10.4%, which reflects the investments of the company to growing the whole market of companion animals. Other things we have to mention is the international operations. We have here the net revenue that 8.4%, which is higher in Brazil. Of course, we have a very strategic market, but also, we have the reflection and also other financially important issues. This also reflects for operations, because it brings the imported products in. We have a very important result in the international operation. Of course, we have very good work in the branches in Mexico and other countries. It was a very important growth because it reflects the commitment of the company to the international operations agenda. We had an adjustment to the expenses.
We had a going down, which reflects the commitment of the company, which brings the 27.5% deletion of these expenses, which brings the margin higher than the growing. It's very important. We have the R&D investments we brought here, which 6.4%, because we had lots of good projects. In this year, we had lots of releases, we had the costs of the R&D in 2024. This percentile is like 6.4%, its round, but it's important to understand this investment is compared to the big companies and data to get closer. We have this in a continuous opportunities and strategies, of course. As we have here, figures of the company, which was 27.4%, I want to highlight not only the growth of the sales, but also the revenue, the cash availability. We had BRL 100 million, which is higher than the cash availability in 2024.
The company has kept this cycle of growing of the net of cash availability, which has been representing a good management of this cash, which makes us much more comfortable to work in this growth. Not only in the sales, but also in the cash availability. In a year, we diluted 10-year values at BRL 220.8 million. Which represents a very healthy cash availability. We have here the structure, capture structure, because it triggers a very good growth, which is 0.85, which is accelerated, which is less in the market, which is less than the EBITDA. Considering that these expenses is related to our investment profile, which is concentrated in the credit, which is allowed to development, which brings the rate of 15% more.
Also, we have an expenses which brings the cost of capital, which is direct to our investment profile, which is very long in our cycle. We had a very below expenses debt, like 39.4% maturing in more than five years. We have seen how this is committed to the interest payments, and it's a very comfortable moment of the company, because it shows that our investment agenda is very committed to the market, mainly to release new products. We have closed the financial information. We are opening the Q&A to Kleber.
Taking a look at the chat, we have no questions so far. A minute, we have one. Going to one. I wasn't able to read the questions. There's a question to explore a little bit more our strategic plan.
Regarding our strategic plan, we are following the same path, we can say that way. We have the plan to intensify our growing in Latin America. We have been working with Mexico. In Mexico, we have a very receptive image, we can see that this is a very important investment. We have been investing in biologics. We also have some plans because we have some global products, we also need to prepare the company. We have efficiency agenda, which is very important, especially to collect new market opportunities, which represents an enhancement of marketing sales. We have been working a very important agenda to develop these teams, these groups, to growth in this. Of course, we still have a lot. We have a products agenda, which has been collecting the products which has the best opportunities in the market.
We still have an organic agenda, it's related to the partners I have mentioned so far. Our commitment is to bring the company as the most admirable company in the world. There's another question regarding a plan of extraordinary distribution of expenses. We don't have it, we have an agenda for the next assemblies. We are going to have this above the minimum. We have the cash to have this money. We must have the agreement of the authorization board. We have in the future as a purpose and agenda of distribution of expenses. There's another question, what is the level of growth of 2026? We can say for sure we have a guidance to follow, we want to grow more than the previous year.
As I mentioned before, we had some products which was launched, released at the end of the year. We still have a lot to consolidate of revenue, that it's important to guarantee the goals we still have. We need to follow the guidance, in the future on, we are going to have more information. That was the questions. We have no other ones. First of all, we want to thank our stockholders, mainly ones, the Mitsui, which is in our board. The Ourofino board, which are always working to bring the best results. Our business partners, our clients, which has been working with Ourof ino. We have to remind that without this structure, we wouldn't be able to do anything. It's important to understand that. We hope you all have a very good 2026, this is what we've committed here.
Now I give the stage to Marcelo.
Thank you, Kleber. I will also thank you all, everyone that supports our job, our work here. The ROI team is always ready to answer any doubts you have, and we hope that 2026 is very prosperous to everyone.